Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Researchers developed a mouse model to evaluate the mechanism of action for ruxolitinib in myeloproliferative neoplasms. They concluded that ruxolitinib acts largely independently of oncogenic JAK2-V617F signaling and reduces the main features of myeloproliferative neoplasms, such as spleen size and leukocyte counts.